SOPHiA GENETICS SA·4

Apr 3, 6:58 AM ET

Van Well Daan 4

4 · SOPHiA GENETICS SA · Filed Apr 3, 2026

Research Summary

AI-generated summary of this filing

Updated

SOPHiA GENETICS (SOPH) Chief Legal Officer Receives RSU & Option Award

What Happened Van Well Daan, Chief Legal Officer of SOPHiA GENETICS SA (SOPH), was granted equity awards on April 2, 2026. The Form 4 reports two awards: 97,536 restricted stock units (RSUs) and 142,216 derivative/share option awards, both recorded at $0.00 (compensation grants), for a combined total of 239,752 shares. These are compensation grants (awards), not open-market purchases or sales, and do not represent immediate cash proceeds.

Key Details

  • Transaction date: April 2, 2026 (filed April 3, 2026). Transaction code: A (award/grant).
  • Awards: 97,536 RSUs (F1) and 142,216 derivative/share option awards (F2); both acquired at $0.00.
  • Vesting (per footnotes):
    • RSUs (F1): 25% vest on April 2, 2027; remaining 75% vest in equal quarterly installments through April 2, 2030.
    • Share option (F2): 25% vests April 2, 2027; then vests in equal monthly installments through April 2, 2030.
  • Shares owned after transaction: not specified in the provided filing.
  • Filing timeliness: filed the business day after the transaction (Form 4 due within 2 business days) — appears timely.

Context These awards are standard compensation for executives and vest over multiple years, so they are not immediately sellable shares. Because these are grants (not purchases or sales), they indicate executive compensation allocation rather than a direct buy/sell signal about management's near-term view of the stock.

Insider Transaction Report

Form 4
Period: 2026-04-02
Van Well Daan
Chief Legal Officer
Transactions
  • Award

    Ordinary Shares

    [F1]
    2026-04-02+97,53697,536 total
  • Award

    Share Option (Right to Buy)

    [F2]
    2026-04-02+142,216142,216 total
    Exercise: $5.04Exp: 2036-04-02Ordinary Shares (142,216 underlying)
Footnotes (2)
  • [F1]Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
  • [F2]The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Signature
/s/ Elimara Brunetto as Attorney-in-Fact for Daan van Well|2026-04-03

Documents

1 file
  • 4
    wk-form4_1775213927.xmlPrimary

    FORM 4